Development of mRNA vaccine against Measles virus globally | ||
| Middle East Journal of Medical Genetics | ||
| Volume 12, Issue 1, January 2023, Pages 1-10 PDF (636.29 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mxe.2024.241269.1007 | ||
| Author | ||
| Mohammed M Kassab* | ||
| Instructor of microbiology,immunology,faculty of pharmacy,Cairo university,Egypt Specialist of pharmacology, toxicology and clinical pharmacy. | ||
| Abstract | ||
| Background: Nowadays, Measles is a dangerous, perhaps fatal viral infection that affects children and newborns in particular. The respiratory tract's mucosal cells are the only area where the infection may first spread before moving on to nearby lymph nodes and eventually, via the blood, to other organs including the skin. Immunity lasts for life. Aim of Study: Widespread utility of the LNP-mRNA Measles vaccine to protect against lethal Measles viral infection. The type of the study: Screening experimental study. Patients and Methods: In the current work, an envelope spike Haemagglutinin protein of Measles vaccine made of lipid nanoparticles was developed. Lipid nanoparticles [LNPs] with a particle size of around 100 nanometer were used as the drug delivery system for the vaccination. By using a hot micro-emulsion process, lipid nanoparticles were created. Results: In randomized clinical studies including humans, the vaccine's effectiveness was 76%, while in preclinical animal research, it was 90%. Compared to the conventional live attenuated Measles vaccination, it demonstrated equivalent biological activity and fewer side effects. The consequence lasted for a long time. In the current investigation, the vaccination proved beneficial as a preventative measure against viral infection. Because fewer amyloid plaques formed in the brain and spinal cord, it did not induce dementia as the earlier immunizations did. This was because it only had trace levels of mRNA. The antibody dependent enhancement in this vaccination, which causes the development of non-protective antibodies, was absent. By activating cytokines and the complement cascade through the production of immunological complexes, these non-neutralizing antibodies worsen infection. The market-purchased killed vaccination demonstrated the antibody-dependent enhancement. Strong antibodies that neutralize the measles virus's haemagglutinin antigen were created by the current vaccination. It took roughly 5 mcg/ml of vaccine to immunize 50% of the applicants who got it (ED 50%). Conclusion: The capacity to create a preventative lipid nanoparticles mRNA Measles vaccine by bioinformatics, which showed promising immunogenicity reached 76%, enabled the current study to contribute to the worldwide eradication of life-threatening Measles viral infectious illnesses among newborns and young children. | ||
| Keywords | ||
| Infection; Measles virus; mRNA; Prophylaxis; Vaccine | ||
|
Statistics Article View: 249 PDF Download: 475 |
||
